Search clinical trials for: Crizotinib

Total 130 results

Mothaffar Rimawi

Terminated

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer (CRIZENT)

Breast Cancer

United States
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...

Not yet recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms (Drugs-SNPs)

Non-Small Cell Lung Cancer

United States
Pfizer

Completed

A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation

Healthy

Belgium
Pfizer

Withdrawn

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Carcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
Samsung Medical Center

Completed

A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

c-MET Positive Gastric Cancer

Korea, Republic of
Pfizer

Completed

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

Renal Impairment

United States
Pfizer

Completed

Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule

Healthy

Belgium
Pfizer

Completed

Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers

Healthy

Belgium
European Organisation for Research and Treatment...
Pfizer

Completed

CREATE: Cross-tumoral Phase 2 With Crizotinib (CREATE)

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 | Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma | Locally Advanced... and other conditions

France, Belgium, Netherlands, Germany, United Kingdom, Italy, Norway, Poland, Slovakia, Slovenia
Pfizer

Completed

A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers

Healthy Volunteer

United States
Jun Zhu
Peking University First Hospital; Peking University People's Hospital; Peking... and other collaborators

Withdrawn

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Systemic Anaplastic Large-Cell Lymphoma

China
National Cheng-Kung University Hospital
Kaohsiung Medical University; Kaohsiung Veterans General Hospital.; Chi Mei Medical...

Recruiting

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Endometrial Cancer Recurrent

Taiwan
Qilu Pharmaceutical Co., Ltd.

Unknown

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer

China
Xcovery Holding Company, LLC

Active, not recruiting

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer

Spain, United States, China, Korea, Republic of, Canada, Hong Kong, United Kingdom, Turkey, Belgium, France, Poland, Israel, Australia, Argentina, Brazil, Czechia, Germany, Italy, Netherlands, Peru, Russian Federation
Harbin Medical University

Completed

Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients

ALK Phosphorylation

China
University of Milano Bicocca

Completed

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Anaplastic Large Cell Lymphoma, ALK-Positive

Italy
Pfizer

No longer available

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Neoplasms | Carcinoma, Non-Small-Cell Lung

Japan
Pfizer

Completed

Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

Advanced Cancer

United States
Pfizer

Completed

A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers

Healthy

United States
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Non-small Cell Lung Cancer

China
Pfizer

Recruiting

Safety and Efficacy of Xalkori ROS1

Non-small Cell Lung Cancer

Japan
Pfizer

Recruiting

Crizotinib Continuation Clinical Study

NSCLC | IMT | ALCL

China, Taiwan, Japan, Russian Federation, Italy
Pfizer

Completed

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

ALK-positive NSCLC

Sweden
University Hospital Regensburg

Completed

Psychometric Properties of the EORTC QLQ-LC29

Lung Cancer

Germany
Pfizer

Completed

Drug Drug Interaction Study Of Crizotinib With Esomeprazole.

Healthy

Belgium
Pfizer

Completed

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom
Pfizer

Completed

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

Non-small Cell Lung Cancer
Shenzhen TargetRx, Inc.
Sun Yat-sen University

Recruiting

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Memorial Sloan Kettering Cancer Center

Completed

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Advanced Lung Cancer

United States
Pfizer

Completed

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Solid Tumors

United States, Taiwan, Japan, Korea, Republic of, Russian Federation, Hungary, France, Czechia, Germany, Italy, United Kingdom
Pfizer

Completed

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Non-Small Cell Lung Cancer

Spain
Jean M. Tersak, M.D.
Pfizer

No longer available

Treatment With Crizotinib Single Patient Expanded Access IND 134375

Inflammatory Myofibroblastic Tumour
Pfizer

Withdrawn

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
Wake Forest University Health Sciences
Pfizer

Terminated

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Urinary Bladder Neoplasms | Ureteral Neoplasms | Urethral Neoplasms

United States
UNICANCER
Pfizer; National Cancer Institute, France; Fondation ARC

Completed

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (AcSé)

Metastatic Cancer | Solid Tumors | Hematologic Cancers

France
Columbia University
Pfizer

Completed

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Uveal Melanoma

United States
Pfizer

Terminated

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

ALK or ROS1-positive NSCLC

China
University of Cologne
Pfizer; Spanish Lung Cancer Group

Completed

EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer (EUCROSS)

Adenocarcinoma | NSCLC | Lung Cancer

Germany, Spain, Switzerland
VA Long Beach Healthcare System

Completed

Comparing TR Band to Statseal in Conjunction With TR Band

Cardiovascular Diseases | Coronary Artery Disease | Atherosclerosis | Angina Pectoris | Arterial Occlusion | Hematoma | Anticoagulant-Induced Bleeding

United States
Pfizer

Completed

A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066

Healthy

Japan
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure Squamous Cell Carcinoma

Non-small Cell Lung Cancer

China
Ariad Pharmaceuticals

Completed

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)

Carcinoma | Lung Cancer | Non-small Cell Lung Cancer | Advanced Malignancies

United States, Canada, Germany, Spain, Taiwan, Korea, Republic of, Switzerland, Hong Kong, Singapore, Italy, Sweden, United Kingdom, France, Netherlands, Denmark, Australia, Norway, Austria, Luxembourg
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

ALK-positive NSCLC

China
Pfizer

Completed

Relative Drug Exposures Of Two Formulations of PF-02341066

Healthy

United States
University Health Network, Toronto
Pfizer

Recruiting

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | ROS1 Gene Rearrangement | MET Activating Mutation | MET Amplification

Canada
Pfizer
OxOnc Development LP

Completed

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Non Small Cell Lung Cancer | Crizotinib | ROS1 Proto Oncogene

Korea, Republic of, China, Taiwan, Japan

Search clinical trials for: Crizotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations